A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 170 participants.
Also called NCT01628120
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 170 participants
- Sponsor
- Registry
-
NCT01628120
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT01628120. Allocation not applicable; no masking; primary purpose treatment. Start 2012-05-31 (actual); primary completion 2015-02-13 (actual). Results posted on 2018-07-19.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase 3, Long-Term Safety Study of Subcutaneous Epoetin Hospira in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME -Anemia Management With Epoetin
- Acronym
- AiME - 04
- Condition
- Chronic Renal Failure Requiring Hemodialysis
- Intervention (Biological)
- Epoetin Hospira
- Lead sponsor
- Pfizer
Record details
- Record id
cardio:ct-nct01628120- Content hash
db67842dbee15561dc6b7123ba99228c8cb855abcaec1322c6bc0171ad2d6c56